questionsmedicales.fr
Actions chimiques et utilisations
Actions pharmacologiques
Utilisations thérapeutiques
Agents cardiovasculaires
Agents cardiovasculaires : Questions médicales fréquentes
Diagnostic
5
Hypertension
Sphygmomanométrie
Insuffisance cardiaque
Échocardiographie
Maladie coronarienne
Angine de poitrine
Arythmie
Électrocardiogramme
Embolie pulmonaire
Tomodensitométrie
Symptômes
5
Crise cardiaque
Douleur thoracique
Insuffisance cardiaque
Œdème
Maladie vasculaire périphérique
Douleur
Prévention
5
Prévention
Maladies cardiovasculaires
Stress
Maladies cardiaques
Traitements
5
Hypertension
Médicaments antihypertenseurs
Insuffisance cardiaque
Traitement
Maladie coronarienne
Stents
Angine de poitrine
Traitement
Complications
5
Insuffisance cardiaque
Complications
Hypertension
Complications
Maladie coronarienne
Complications
Facteurs de risque
5
Facteurs de risque
Maladies cardiovasculaires
Tabagisme
Maladies cardiaques
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Agents cardiovasculaires : Questions médicales les plus fréquentes",
"headline": "Agents cardiovasculaires : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Agents cardiovasculaires : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-05-18",
"dateModified": "2026-08-06",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Agents cardiovasculaires"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Utilisations thérapeutiques",
"url": "https://questionsmedicales.fr/mesh/D045506",
"about": {
"@type": "MedicalCondition",
"name": "Utilisations thérapeutiques",
"code": {
"@type": "MedicalCode",
"code": "D045506",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.954"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Antiarythmiques",
"alternateName": "Anti-Arrhythmia Agents",
"url": "https://questionsmedicales.fr/mesh/D000889",
"about": {
"@type": "MedicalCondition",
"name": "Antiarythmiques",
"code": {
"@type": "MedicalCode",
"code": "D000889",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.954.411.097"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Antihypertenseurs",
"alternateName": "Antihypertensive Agents",
"url": "https://questionsmedicales.fr/mesh/D000959",
"about": {
"@type": "MedicalCondition",
"name": "Antihypertenseurs",
"code": {
"@type": "MedicalCode",
"code": "D000959",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.954.411.162"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs des canaux calciques",
"alternateName": "Calcium Channel Blockers",
"url": "https://questionsmedicales.fr/mesh/D002121",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs des canaux calciques",
"code": {
"@type": "MedicalCode",
"code": "D002121",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.954.411.192"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Natriurétiques",
"alternateName": "Natriuretic Agents",
"url": "https://questionsmedicales.fr/mesh/D045283",
"about": {
"@type": "MedicalCondition",
"name": "Natriurétiques",
"code": {
"@type": "MedicalCode",
"code": "D045283",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.954.411.455"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Donneur d'oxyde nitrique",
"alternateName": "Nitric Oxide Donors",
"url": "https://questionsmedicales.fr/mesh/D020030",
"about": {
"@type": "MedicalCondition",
"name": "Donneur d'oxyde nitrique",
"code": {
"@type": "MedicalCode",
"code": "D020030",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.954.411.590"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs des canaux potassiques",
"alternateName": "Potassium Channel Blockers",
"url": "https://questionsmedicales.fr/mesh/D026902",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs des canaux potassiques",
"code": {
"@type": "MedicalCode",
"code": "D026902",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.954.411.645"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Bloqueurs de canaux sodiques",
"alternateName": "Sodium Channel Blockers",
"url": "https://questionsmedicales.fr/mesh/D026941",
"about": {
"@type": "MedicalCondition",
"name": "Bloqueurs de canaux sodiques",
"code": {
"@type": "MedicalCode",
"code": "D026941",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.954.411.720"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Bloqueurs de canaux sodiques voltage-dépendants",
"alternateName": "Voltage-Gated Sodium Channel Blockers",
"url": "https://questionsmedicales.fr/mesh/D061567",
"about": {
"@type": "MedicalCondition",
"name": "Bloqueurs de canaux sodiques voltage-dépendants",
"code": {
"@type": "MedicalCode",
"code": "D061567",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.954.411.720.500"
}
}
}
]
},
{
"@type": "MedicalWebPage",
"name": "Vasoconstricteurs",
"alternateName": "Vasoconstrictor Agents",
"url": "https://questionsmedicales.fr/mesh/D014662",
"about": {
"@type": "MedicalCondition",
"name": "Vasoconstricteurs",
"code": {
"@type": "MedicalCode",
"code": "D014662",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.954.411.793"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Agonistes des canaux calciques",
"alternateName": "Calcium Channel Agonists",
"url": "https://questionsmedicales.fr/mesh/D002120",
"about": {
"@type": "MedicalCondition",
"name": "Agonistes des canaux calciques",
"code": {
"@type": "MedicalCode",
"code": "D002120",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.954.411.793.205"
}
}
}
]
},
{
"@type": "MedicalWebPage",
"name": "Vasodilatateurs",
"alternateName": "Vasodilator Agents",
"url": "https://questionsmedicales.fr/mesh/D014665",
"about": {
"@type": "MedicalCondition",
"name": "Vasodilatateurs",
"code": {
"@type": "MedicalCode",
"code": "D014665",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.954.411.918"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Facteurs de relaxation dépendants de l'endothélium",
"alternateName": "Endothelium-Dependent Relaxing Factors",
"url": "https://questionsmedicales.fr/mesh/D045462",
"about": {
"@type": "MedicalCondition",
"name": "Facteurs de relaxation dépendants de l'endothélium",
"code": {
"@type": "MedicalCode",
"code": "D045462",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.954.411.918.500"
}
}
}
]
}
],
"about": {
"@type": "MedicalCondition",
"name": "Agents cardiovasculaires",
"alternateName": "Cardiovascular Agents",
"code": {
"@type": "MedicalCode",
"code": "D002317",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Juan Tamargo",
"url": "https://questionsmedicales.fr/author/Juan%20Tamargo",
"affiliation": {
"@type": "Organization",
"name": "Department of Pharmacology and Toxicology, School of Medicine, Universidad Complutense, Instituto De Investigación Sanitaria Gregorio Marañón, Madrid, Spain."
}
},
{
"@type": "Person",
"name": "Stefan Agewall",
"url": "https://questionsmedicales.fr/author/Stefan%20Agewall",
"affiliation": {
"@type": "Organization",
"name": "Department of Cardiology, Oslo University Hospital and Institute of Clinical Medicine, Oslo University, Oslo, Norvay."
}
},
{
"@type": "Person",
"name": "Claudio Borghi",
"url": "https://questionsmedicales.fr/author/Claudio%20Borghi",
"affiliation": {
"@type": "Organization",
"name": "Department of Cardiovascular Medicine, University of Bologna-IRCCS AOU S. Orsola, Bologna, Italy."
}
},
{
"@type": "Person",
"name": "Claudio Ceconi",
"url": "https://questionsmedicales.fr/author/Claudio%20Ceconi",
"affiliation": {
"@type": "Organization",
"name": "Unit of Cardiologia, ASST Garda, Desenzano del Garda, Italy."
}
},
{
"@type": "Person",
"name": "Elisabetta Cerbai",
"url": "https://questionsmedicales.fr/author/Elisabetta%20Cerbai",
"affiliation": {
"@type": "Organization",
"name": "Department Neurofarba, Section of Pharmacology and Toxicology, University of Florence, Italy."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Novel Therapies for the Treatment of Cardiovascular Disease.",
"datePublished": "2024-04-12",
"url": "https://questionsmedicales.fr/article/39084843",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.mcna.2024.03.003"
}
},
{
"@type": "ScholarlyArticle",
"name": "Adherence to cardiovascular medications and risk of cardiovascular disease in breast cancer patients: A causal inference approach in the Pathways Heart Study.",
"datePublished": "2024-09-19",
"url": "https://questionsmedicales.fr/article/39298390",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1371/journal.pone.0310531"
}
},
{
"@type": "ScholarlyArticle",
"name": "Pharmacogenomics of Cardiovascular Drugs for Atherothrombotic, Thromboembolic and Atherosclerotic Risk.",
"datePublished": "2023-11-09",
"url": "https://questionsmedicales.fr/article/38003001",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3390/genes14112057"
}
},
{
"@type": "ScholarlyArticle",
"name": "Extracorporeal membrane oxygenation in cardiovascular medication poisoning. A German-wide retrospective study.",
"datePublished": "2024-09-18",
"url": "https://questionsmedicales.fr/article/39294292",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1038/s41598-024-72547-0"
}
},
{
"@type": "ScholarlyArticle",
"name": "Benefits of the Polypill on Medication Adherence in the Primary and Secondary Prevention of Cardiovascular Disease: A Systematic Review.",
"datePublished": "2023-09-12",
"url": "https://questionsmedicales.fr/article/37719697",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.2147/VHRM.S421024"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Actions chimiques et utilisations",
"item": "https://questionsmedicales.fr/mesh/D020164"
},
{
"@type": "ListItem",
"position": 3,
"name": "Actions pharmacologiques",
"item": "https://questionsmedicales.fr/mesh/D020228"
},
{
"@type": "ListItem",
"position": 4,
"name": "Utilisations thérapeutiques",
"item": "https://questionsmedicales.fr/mesh/D045506"
},
{
"@type": "ListItem",
"position": 5,
"name": "Agents cardiovasculaires",
"item": "https://questionsmedicales.fr/mesh/D002317"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Agents cardiovasculaires - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Agents cardiovasculaires",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2026-08-25",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Agents cardiovasculaires",
"description": "Comment diagnostiquer une hypertension artérielle ?\nQuels tests pour évaluer l'insuffisance cardiaque ?\nQuels signes indiquent une maladie coronarienne ?\nComment détecter une arythmie cardiaque ?\nQuels examens pour une embolie pulmonaire ?",
"url": "https://questionsmedicales.fr/mesh/D002317#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Agents cardiovasculaires",
"description": "Quels sont les symptômes d'une crise cardiaque ?\nComment reconnaître une hypertension ?\nQuels signes d'insuffisance cardiaque ?\nQuels symptômes d'arythmie ?\nQuels symptômes d'une maladie vasculaire périphérique ?",
"url": "https://questionsmedicales.fr/mesh/D002317#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Agents cardiovasculaires",
"description": "Comment prévenir les maladies cardiovasculaires ?\nQuel rôle de l'exercice dans la santé cardiaque ?\nComment réduire le cholestérol ?\nQuel impact du stress sur le cœur ?\nComment éviter l'hypertension ?",
"url": "https://questionsmedicales.fr/mesh/D002317#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Agents cardiovasculaires",
"description": "Quels médicaments pour l'hypertension ?\nComment traiter l'insuffisance cardiaque ?\nQuels traitements pour les arythmies ?\nComment traiter une maladie coronarienne ?\nQuels traitements pour l'angine de poitrine ?",
"url": "https://questionsmedicales.fr/mesh/D002317#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Agents cardiovasculaires",
"description": "Quelles complications de l'insuffisance cardiaque ?\nQuels risques d'une crise cardiaque ?\nQuelles complications de l'hypertension ?\nQuels effets d'une arythmie non traitée ?\nQuelles complications de la maladie coronarienne ?",
"url": "https://questionsmedicales.fr/mesh/D002317#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Agents cardiovasculaires",
"description": "Quels sont les principaux facteurs de risque cardiovasculaires ?\nQuel rôle du tabagisme dans les maladies cardiaques ?\nComment le diabète affecte-t-il le cœur ?\nQuel impact de l'obésité sur la santé cardiaque ?\nComment l'âge influence-t-il le risque cardiovasculaire ?",
"url": "https://questionsmedicales.fr/mesh/D002317#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une hypertension artérielle ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "La mesure répétée de la pression artérielle avec un sphygmomanomètre est essentielle."
}
},
{
"@type": "Question",
"name": "Quels tests pour évaluer l'insuffisance cardiaque ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'échocardiographie et les dosages de peptides natriurétiques sont courants."
}
},
{
"@type": "Question",
"name": "Quels signes indiquent une maladie coronarienne ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des douleurs thoraciques, essoufflement et fatigue peuvent signaler une maladie coronarienne."
}
},
{
"@type": "Question",
"name": "Comment détecter une arythmie cardiaque ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un électrocardiogramme (ECG) est utilisé pour identifier les arythmies cardiaques."
}
},
{
"@type": "Question",
"name": "Quels examens pour une embolie pulmonaire ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "La tomodensitométrie (TDM) et l'angiographie pulmonaire sont des examens clés."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes d'une crise cardiaque ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Douleur thoracique, essoufflement, sueurs et nausées sont des symptômes fréquents."
}
},
{
"@type": "Question",
"name": "Comment reconnaître une hypertension ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Souvent asymptomatique, elle peut causer maux de tête ou vertiges dans certains cas."
}
},
{
"@type": "Question",
"name": "Quels signes d'insuffisance cardiaque ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Essoufflement, œdème des membres inférieurs et fatigue sont des indicateurs clés."
}
},
{
"@type": "Question",
"name": "Quels symptômes d'arythmie ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Palpitations, vertiges et fatigue peuvent indiquer une arythmie cardiaque."
}
},
{
"@type": "Question",
"name": "Quels symptômes d'une maladie vasculaire périphérique ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Douleurs aux jambes lors de la marche et engourdissements sont des signes courants."
}
},
{
"@type": "Question",
"name": "Comment prévenir les maladies cardiovasculaires ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Adopter une alimentation saine, faire de l'exercice et éviter le tabac sont essentiels."
}
},
{
"@type": "Question",
"name": "Quel rôle de l'exercice dans la santé cardiaque ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'exercice régulier renforce le cœur et améliore la circulation sanguine."
}
},
{
"@type": "Question",
"name": "Comment réduire le cholestérol ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation équilibrée et des médicaments comme les statines peuvent aider."
}
},
{
"@type": "Question",
"name": "Quel impact du stress sur le cœur ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le stress chronique peut augmenter le risque de maladies cardiaques et d'hypertension."
}
},
{
"@type": "Question",
"name": "Comment éviter l'hypertension ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Réduire le sel, maintenir un poids santé et faire de l'exercice sont des mesures clés."
}
},
{
"@type": "Question",
"name": "Quels médicaments pour l'hypertension ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les diurétiques, bêtabloquants et inhibiteurs de l'ECA sont souvent prescrits."
}
},
{
"@type": "Question",
"name": "Comment traiter l'insuffisance cardiaque ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les diurétiques, inhibiteurs de l'ECA et bêtabloquants sont des options de traitement."
}
},
{
"@type": "Question",
"name": "Quels traitements pour les arythmies ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les antiarythmiques, cardioversion et ablation sont des traitements possibles."
}
},
{
"@type": "Question",
"name": "Comment traiter une maladie coronarienne ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les stents, pontages et médicaments comme les statines sont des options de traitement."
}
},
{
"@type": "Question",
"name": "Quels traitements pour l'angine de poitrine ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les nitrates, bêtabloquants et modifications du mode de vie sont recommandés."
}
},
{
"@type": "Question",
"name": "Quelles complications de l'insuffisance cardiaque ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent l'œdème pulmonaire, l'arythmie et le choc cardiogénique."
}
},
{
"@type": "Question",
"name": "Quels risques d'une crise cardiaque ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les risques incluent l'insuffisance cardiaque, l'arythmie et la mort subite."
}
},
{
"@type": "Question",
"name": "Quelles complications de l'hypertension ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'hypertension peut entraîner des AVC, des maladies rénales et des maladies cardiaques."
}
},
{
"@type": "Question",
"name": "Quels effets d'une arythmie non traitée ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une arythmie non traitée peut provoquer des AVC, une insuffisance cardiaque ou la mort."
}
},
{
"@type": "Question",
"name": "Quelles complications de la maladie coronarienne ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent l'infarctus du myocarde, l'angine et l'insuffisance cardiaque."
}
},
{
"@type": "Question",
"name": "Quels sont les principaux facteurs de risque cardiovasculaires ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'hypertension, le tabagisme, le diabète et l'obésité sont des facteurs majeurs."
}
},
{
"@type": "Question",
"name": "Quel rôle du tabagisme dans les maladies cardiaques ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le tabagisme endommage les vaisseaux sanguins et augmente le risque de maladies cardiaques."
}
},
{
"@type": "Question",
"name": "Comment le diabète affecte-t-il le cœur ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le diabète augmente le risque de maladies cardiovasculaires en affectant la circulation."
}
},
{
"@type": "Question",
"name": "Quel impact de l'obésité sur la santé cardiaque ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'obésité augmente le risque d'hypertension, de diabète et de maladies cardiaques."
}
},
{
"@type": "Question",
"name": "Comment l'âge influence-t-il le risque cardiovasculaire ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le risque de maladies cardiovasculaires augmente avec l'âge en raison de divers facteurs."
}
}
]
}
]
}
Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale
Validation scientifique effectuée le 06/08/2026
Contenu vérifié selon les dernières recommandations médicales
2 publications dans cette catégorie
Affiliations :
Department of Pharmacology and Toxicology, School of Medicine, Universidad Complutense, Instituto De Investigación Sanitaria Gregorio Marañón, Madrid, Spain.
Publications dans "Agents cardiovasculaires" :
2 publications dans cette catégorie
Affiliations :
Department of Cardiology, Oslo University Hospital and Institute of Clinical Medicine, Oslo University, Oslo, Norvay.
Publications dans "Agents cardiovasculaires" :
2 publications dans cette catégorie
Affiliations :
Department of Cardiovascular Medicine, University of Bologna-IRCCS AOU S. Orsola, Bologna, Italy.
Publications dans "Agents cardiovasculaires" :
2 publications dans cette catégorie
Affiliations :
Unit of Cardiologia, ASST Garda, Desenzano del Garda, Italy.
Publications dans "Agents cardiovasculaires" :
2 publications dans cette catégorie
Affiliations :
Department Neurofarba, Section of Pharmacology and Toxicology, University of Florence, Italy.
Publications dans "Agents cardiovasculaires" :
2 publications dans cette catégorie
Affiliations :
"Carol Davila" University of Medicine, Colentina University Hospital, Bucharest, Romania.
Publications dans "Agents cardiovasculaires" :
2 publications dans cette catégorie
Affiliations :
Department of Pharmacology and Pharmacotherapy, Semmelweis University, Budapest, Hungary.
Pharma hungary Group, Szeged, Hungary.
Publications dans "Agents cardiovasculaires" :
2 publications dans cette catégorie
Affiliations :
Department of Cardiology, Aarhus University Hospital, Aarhus, Denmark.
Department of Clinical Medicine, Faculty of Health, Aarhus University, Aarhus, Denmark).
Publications dans "Agents cardiovasculaires" :
2 publications dans cette catégorie
Affiliations :
Section of Pharmacology, Catholic University School of Medicine, Rome, Italy.
Publications dans "Agents cardiovasculaires" :
2 publications dans cette catégorie
Affiliations :
Department of Medicine, Division of Cardiology, Medical University of Vienna, Austria.
Publications dans "Agents cardiovasculaires" :
2 publications dans cette catégorie
Affiliations :
Preventive Cario-Rheuma clinic, Division of Research and Innovation, REMEDY centre, Diakonhjemmet Hospital, Oslo, Norway.
Publications dans "Agents cardiovasculaires" :
2 publications dans cette catégorie
Affiliations :
Department of Internal Medicine II, University Regensburg, Germany.
Publications dans "Agents cardiovasculaires" :
2 publications dans cette catégorie
Affiliations :
Department of Internal Medicine II, Division of Cardiology, Medical University of Vienna, Austria.
Publications dans "Agents cardiovasculaires" :
2 publications dans cette catégorie
Affiliations :
Molecular and Clinical Sciences Research Institute, St. George's, University of London, Cranmer Terrace, London SW17 0RE, UK.
Publications dans "Agents cardiovasculaires" :
2 publications dans cette catégorie
Affiliations :
Institute of Pharmacology, West-German Heart and Vascular Centre, University Duisburg-Essen, Essen, Germany.
Department of Medicine, Montreal Heart Institute and Université de Montréal, Montréal, Canada.
Department of Molecular Physiology & Biophysics, Baylor College of Medicine, Houston, TX, USA.
Publications dans "Agents cardiovasculaires" :
2 publications dans cette catégorie
Publications dans "Agents cardiovasculaires" :
2 publications dans cette catégorie
Affiliations :
School of Environmental Science and Engineering, Shanghai Jiao Tong University, 800 Dongchuan Road, Shanghai 200240, China; Shanghai Institute of Pollution Control and Ecological Security, Shanghai 200092, China.
Publications dans "Agents cardiovasculaires" :
2 publications dans cette catégorie
Affiliations :
School of Environmental Science and Engineering, Shanghai Jiao Tong University, 800 Dongchuan Road, Shanghai 200240, China; Shanghai Institute of Pollution Control and Ecological Security, Shanghai 200092, China. Electronic address: zhaoyanbin@sjtu.edu.cn.
Publications dans "Agents cardiovasculaires" :
1 publication dans cette catégorie
Affiliations :
Stanford Cardiovascular Institute, Stanford University School of Medicine, Stanford, CA, United States.
Division of Cardiovascular Medicine, Department of Medicine, Stanford University, Stanford, CA, United States.
Publications dans "Agents cardiovasculaires" :
1 publication dans cette catégorie
Affiliations :
Stanford Cardiovascular Institute, Stanford University School of Medicine, Stanford, CA, United States.
Publications dans "Agents cardiovasculaires" :
Over the last decade, randomized clinical trials of several pharmacologic agents have demonstrated a reduction in cardiovascular mortality and other important secondary outcomes. Angiotensin-Neprilysi...
Women with breast cancer (BC) are at high risk of developing cardiovascular disease (CVD). We examined adherence to CVD medications and their association with major CVD events over 14 years of follow-...
Eligibility included being alive 6 months post-BC diagnosis, with dyslipidemia, hypertension, or diabetes at diagnosis along with ≥1 prior outpatient order or dispensing for a statin, anti-hypertensiv...
Poor statin adherence (CAA<80%) was associated with higher risk of composite CVD (HR = 2.54; 95% CI: 1.09, 5.94) versus CAA≥80%. Poor statin adherence was also associated with a higher risk of stroke ...
Maintaining good adherence (≥80%) to statins after BC treatment is beneficial for cardiovascular health in patients with dyslipidemia. Future studies should determine factors associated with lower adh...
Advances in pharmacogenomics have paved the way for personalized medicine. Cardiovascular diseases still represent the leading cause of mortality in the world. The aim of this review is to summarize t...
Randomized clinical trials have supported the role of a genotype-guided approach for antiplatelet therapy in patients with coronary heart disease undergoing percutaneous coronary interventions. Numero...
Pharmacogenomics has the potential to improve patient care by providing the right drug to the right patient and could guide the identification of new drug therapies for cardiovascular disease. This is...
Medication poisoning, resulting from the ingestion of cardiotoxic drugs, presents a significant health issue. The mortality rate remains high for patients with myocardial dysfunction refractory to con...
Higher medication adherence reduces the risk of new cardiovascular events. However, there are individual and health system barriers that lead to lower adherence. The polypill has demonstrated benefits...
A systematic review following PRISMA guidelines was conducted. Databases were searched from January 2003 to December 2022. We included randomized, pragmatic, or real-world clinical trials and observat...
From the 490 publications screened, 13 met the inclusion criteria and were incorporated into a comparative table Of those included, 70% were randomized controlled trials (RCTs) and 53.8% focused on se...
The polypill is an effective, safe, and practical strategy to improve adherence in people at risk of CVD. Although there is a demonstrated benefit in reducing MACE, predominantly in secondary preventi...
Global health concerns persist due to the multifaceted nature of heart diseases, which include lifestyle choices, genetic predispositions, and emerging post-COVID complications like myocarditis and pe...
A number of medical conditions are identified as risk factors for suicide death; in particular, cardiovascular illnesses are recognized as a major suicide risk factor. In this case, self-poisoning is ...
Adverse drug reactions (ADRs) represent a significant barrier to achieve optimal treatment outcomes. Cardiovascular drugs, including antihypertensive drugs, lipid-lowering drugs, and antithrombotic dr...
To estimate the prevalence of cardiovascular drug-related ADRs consultations in United Kingdom (UK) primary care and identify risk factors of these ADRs....
This was a cross-sectional study of cardiovascular drug users between 2000-2019 using UK IQVIA Medical Research Data. ADRs consultations were identified using database screening method employing stand...
The standardised prevalence of consultations related to cardiovascular drugs ADRs was 10.60 (95% CI. 10.46, 10.75) per 1000 patients. Patients aged 70-79 years had the highest occurrence of ADRs consu...
The burden of cardiovascular drug-related ADRs consultations in primary care was considerable. Statins, beta-blockers, ACEIs/ARBs, and aspirin were the most frequently implicated drug classes. Closer ...
Cardiovascular drug development requires synthesizing relevant literature about indications, mechanisms, biomarkers, and outcomes. This short study investigates the performance, cost, and prompt engin...
Cardiovascular disease is a major cause of mortality and morbidity worldwide, and primary prevention efforts are poorly developed in people at high cardiovascular risk. On this background, we performe...
A random sample from the original Hjerteløftet Study was included for further examinations (n = 255, 40% women), and these patients were already randomized to an intervention group (IG) (n = 127), or ...
Self-reported physical activity increased significantly with absolute difference in mean delta Physical Activity Index score in the IG compared to the CG: 0.90, 95% CI: 0.10 to 1.70, p = 0.028 (ANCOVA...
Participation in the Hjerteløftet Study intervention programme resulted in an improved physical activity level, but without changing cardiorespiratory fitness. Participation in the programme also tend...
ClinicalTrials.gov (NCT01741428), 04/12/2012....